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C L I N I C A L R E S E A R C H A R T I C L E
Neurokinin B Regulates Gonadotropin Secretion,
Ovarian Follicle Growth, and the Timing of
Ovulation in Healthy Women
Karolina Skorupskaite,1 Jyothis T. George,2,3 Johannes D. Veldhuis,4
and Richard A. Anderson1
1MRC Centre for Reproductive Health, The Queen’s Medical Research Institute, University of Edinburgh,
Edinburgh EH16 4TJ, United Kingdom; 2Warwick Medical School, Coventry CV4 7AL, United Kingdom;
3Boehringer Ingelheim, Bracknell RG12 8YS, United Kingdom; and 4Endocrine Research Unit, Center for
Translational Science Activities, Mayo Clinic, Rochester, Minnesota 55905
Context: Neurokinin B (NKB) is obligate for human puberty, but its role in adult female gonado-
tropin secretion and ovarian follicle growth is unknown.
Objective: To investigate antagonism of NKB on pulsatile gonadotropin-releasing hormone (GnRH)
and luteinizing hormone (LH) secretion and ovarian follicle development in healthy women.
Design:Open investigation of the effects of a neurokinin-3 receptor (NK3R) antagonist (NK3Ra) vs a
no-treatment control cycle.
Setting: Clinical research facility.
Patients or other participants: Healthy women with regular menses (n = 13).
Intervention(s): NK3Ra MLE4901 40 mg taken orally twice daily from cycle day 5 to 6 for 7 days.
Main outcome measure(s): LH secretion, ovarian follicle growth, and timing of ovulation.
Results: NK3Ra administration reduced basal LH secretion without a change in pulse frequency and
delayed the LH surge by 7 days, the duration of treatment [mean cycle day6 standard error of the
mean (SEM), 226 1 days vs 156 1 days in control cycles; P = 0.0006]. Follicle growth (mean diameter
at the end of administration of NK3Ra administration 6 SEM, 9.3 6 0.4 mm vs 15.1 6 0.9 mm in
control cycles; P , 0.0001) and rising estradiol concentrations (mean 6 SEM, 166 6 29 pmol/L vs
4466 86 pmol/L in control cycles; P, 0.0001) were prevented. After treatment, follicle development
resumed and normal preovulatory follicle diameter and estradiol concentrations were demonstrated.
Postovulatory progesterone rise was similarly delayed (peak cycle day, 306 2 vs 226 1; P = 0.002) and
cycle length was prolonged (35 6 1 days vs 29 6 1 days in control cycles; P = 0.0003) but luteal
progesterone excretion was unaffected by the NK3Ra (LH surge day +7 mean urinary progesterone
levels 6 SEM, 58 6 10 pmol/mol vs 4867 pmol/mol creatinine in control cycles; nonsignificant).
Conclusion: These data demonstrate the involvement of NKB-NK3R signaling in the physiological
regulation of GnRH/LH secretion, determining normal follicle development in women. (J Clin
Endocrinol Metab 103: 95–104, 2018)
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Abbreviations: ANOVA, analysis of variance; CV, coefficient of variation; ELISA, enzyme-
linked immunosorbent assay; FSH, follicle-stimulating hormone; GnRH, gonadotropin-
releasing hormone; LH, luteinizing hormone; NK3R, neurokinin-3 receptor; NK3Ra,
neurokinin-3 receptor antagonist; NKB, neurokinin B; ns, nonsignificant; PCOS, polycystic
ovary syndrome; SEM, standard error of the mean.
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There is growing evidence that neurokinin B (NKB) is akey modulator of gonadotropin-releasing hormone
(GnRH) secretion and, hence, of reproductive function in
men and women. Loss-of-function mutations in the genes
encoding NKB (TAC3) and the neurokinin-3 receptor
(TAC3R) result in hypogonadotropic pubertal delay (1).
This is similar to the phenotype of individuals with loss of
function of kisspeptin signaling (2–4), and these neuro-
peptides can be coexpressed in some hypothalamic
neurons (5). However, although kisspeptin administra-
tion results in stimulation of GnRH and luteinizing
hormone (LH) secretion in men and women, albeit var-
iably, according to the stage of the menstrual cycle and
underpinning sex steroid environment (6–9), administra-
tion ofNKBasan intravenous infusion over 3 hours tomen
and women had no effect on reproductive hormone se-
cretion (10). Data from animal studies are also inconclu-
sive; both stimulatory and inhibitory effects of NKB have
been reported in rodent models (11–14). In higher
species, a stimulatory effect of NKB on LH secretion has
been more consistently shown, as demonstrated in ewes
(15, 16), goats (17), and monkeys (18).
Administration of neurokinin-3 receptor (NK3R) an-
tagonist (NK3Ra) has, however, provided evidence of
the involvement of this pathway in human and animal
reproduction through the regulation of GnRH secre-
tion. When administrated to gonadectomized ewes, the
NK3Ra ESN364 and MRK-08 decreased LH secretion
and pulse frequency while follicle-stimulating hormone
(FSH) levels were maintained (16, 19). Administration of
ESN364 throughout the follicular phase in intact non-
human primates inhibited estradiol secretion, with no
LH surge or subsequent rise in serum progesterone level
(19). Similarly, the NK3Ra MLE4901 (formerly known
as AZD4901) resulted in a decrease in LH concentrations
with a reduction in LH pulse frequency in healthy women
during estrogen administration (20) and in women with
polycystic ovary syndrome (PCOS) (21). In healthy
women, ESN364 administration for 21 days from early
in the follicular phase decreased estradiol secretion, al-
though no significant changes in LH concentrations or
follicle development were observed (22). The LH surge,
however, was variably delayed (22). In an analysis of the
interaction with kisspeptin in the regulation of surge-like
LH secretion in health women, MLE4901 shortened the
duration of kisspeptin-stimulated LH secretion (20).
We have explored, therefore, the role of NKB signaling
in the regulation of GnRH and LH secretion and ovarian
function in healthy women using the NK3Ra MLE4901.
The effects of NK3R antagonism on LH secretion and
ovarian follicle development during the follicular phase
of the menstrual cycle were determined in premenopausal
women, demonstrating that NKB-NK3R signaling is im-
portant in the physiological regulation of GnRH-driven
follicle growth and, consequently, the timing of ovulation.
Materials and Methods
Participants
Thirteen healthy, premenopausal women, aged 27 to 41
years and with regular menstrual cycles (25 to 34 days) were
recruited into the study; all provided informed written consent.
Mean 6 standard error of the mean body mass index was
26.6 6 1.6 kg/m2. The women were not taking any hormonal
contraception nor had an intrauterine device in situ. They had
normal physical examination and full blood cell count results;
renal function, electrolyte levels, liver function, and electro-
cardiogram results were within normal limits.
Sample size
The sample size in this and previous studies is based on
similar proof-of-concept mechanistic studies in our laboratory
and by other colleagues, demonstrating significant changes in
reproductive hormone concentrations and in pulsatile LH se-
cretion (7, 9, 23). For LH pulse frequency, power analysis
[based on data reported by Skorupskaite et al (20)] indicates
that with a = 0.05, eight women per group would be required to
show a significant change with 90% power.
Study drug
The NK3Ra MLE4901 was administered orally at 40 mg
twice daily. This dosage of MLE4901 reduced LH secretion in
healthy women and in women with PCOS (20, 21).
Protocol
Investigation of the effect of NK3R antagonism on
gonadotropin and ovarian hormone secretion
Schematic presentation of the protocol is shown in Fig. 1. All
women had a treatment cycle and a no-treatment control cycle,
with a washout cycle in between if the treatment cycle was first;
the order of cycles was randomized using sealed envelopes. In
the treatment cycle, women were administered the specific
NK3RaMLE4901 orally at 40mg twice daily for 7 days starting
on cycle day 5 to 6. Peripheral venous blood was sampled for
LH, FSH, inhibin B, and estradiol concentration measurement
between 08:00 and 10:00 immediately before treatment (pre-
treatment), and on days 2, 4, and 6 of NK3Ra administration
immediately before the next dose of NK3Ra was taken (i.e.,
12 hours after the previous dose), in the morning after the last
dose, and then every 2 to 4 days until ovulation was confirmed
by transvaginal ultrasonography (Xario 200, 7.5 MHz probe
frequency; Toshiba, Zoetermeer, The Netherlands). Ovulation
was defined either by the last day on which the preovulatory
follicle was seen or the appearance of a corpus luteum. In the
control cycle, blood sampling and ultrasound timing were
equivalent to that in the treatment cycle. A first-void specimen of
urine was collected daily throughout the cycle.
Investigation of the effect of NK3R antagonism on
follicle development and endometrial thickness
Transvaginal ultrasonography was used to measure the di-
ameter of the leading follicle, any follicles$10 mm in diameter,
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endometrial thickness, and appearance of corpus luteum. Ul-
trasound scans were performed on the same days as assessment
of reproductive hormone levels.
Investigation of the effect of NK3R antagonism on
LH pulsatility
Assessment of LH pulsatility was performed in eight of the
13 women (owing to the time commitment, not all women
volunteered for this) on day 6 or 7 of NK3Ra treatment or on
cycle day 10 to 12 (the equivalent day) of control cycles. All
visits commenced between 08:00 and 09:00. The dose of
NK3Ra was administered when the pulsatility assessment was
begun; blood samples were collected via an indwelling in-
travenous cannula at 10-minute intervals for 8 hours.
Safety monitoring
Hematological and biochemical safety monitoring was
performed before commencing NK3Ra treatment, at end of
drug administration, and 2 to 3 weeks later.
Hormone assays
Blood samples were centrifuged at 4°C for 10 minutes at
3000 rpm and serum was frozen at 220°C or below until
analysis. LH and FSH levels were measured by enzyme-linked
immunosorbent assay (ELISA) as previously described (23) with
interassay and intra-assay coefficient of variation (CV),5% at
the concentrations measured. 17b-estradiol was measured on a
Roche Cobas E411 immunoassay automated analyzer (Roche
Diagnostics, Burgess Hill, United Kingdom). The lower limit of
quantification was 18.4 pmol/L. The inter- and intra-assay CVs
were ,5% and 6.5%, respectively. Inhibin B was measured by
ELISA (Beckman Coulter, Brae, CA) with a limit of quantifi-
cation 2.6 pg/mL and intra-assay CV ,8%; all samples were
assayed in one run.
Progesterone level was measured by an inhouse ELISA. The
interassay CVs for low and high progesterone pools, re-
spectively, were 11.4%and 9.1%, and the respective intra-assay
CVs were 8.9% and 5.6%. The lower limit of detection was
0.1 ng/mL. Urinary progesterone concentrationswere expressed
as a ratio of the creatinine concentration, measured colori-
metrically (Alpha Laboratories, Eastleigh, United Kingdom),
and adapted for use on a Cobas Fara centrifugal analyzer
(Roche Diagnostics, Welwyn Garden City, United Kingdom).
Intra-assay CV was ,3%; all samples were analyzed in one
batch, in duplicate.
The number of LH pulses, secretory mass of LH per pulse,
and basal (nonpulsatile) and pulsatile (integral of dual ampli-
tude and frequency regulation) LH secretion were identified by
an established deconvolutional algorithm with cluster analysis
(93% sensitivity and specificity) blinded to treatment allocation,
and approximate entropy was quantified as a measure of se-
cretory regularity (24, 25).
Statistical analysis
Baseline characteristics between the control and NK3Ra-
treated cycles were compared by Student paired t test (for
normally distributed data, i.e., LH, FSH, and estradiol levels;
and follicle size) or Wilcoxon matched-pairs signed-rank test
(menstrual cycle day). Serum hormone concentrations and
ultrasonography data were compared throughout 7 days of
NK3Ra treatment and between the control and treatment
groups using repeated measure two-way analysis of variance
(ANOVA) followed by Bonferroni multiple comparisons post
hoc analysis. Peak serum hormone concentration, size of the
preovulatory follicle, and cycle timing were compared by
Student paired t test. Urinary progesterone concentrations
were compared by two-way ANOVA followed by Bonferroni
post hocmultiple comparisons test; these data were available
for 11 women. Midluteal (i.e., LH surge +7 days) urinary
Figure 1. Study protocol schematic. The NK3Ra MLE4901 was administered orally to 13 healthy women for 7 days starting on cycle day 5 to 6.
Reproductive hormones were measured and TV USS was performed pretreatment, on days 2, 4, 6, and 8 during the study, and then every 2 to
4 days until ovulation. Urine samples were collected daily until the next menstrual period. LH pulsatility (n = 8) was assessed during 8 hours of
blood sampling every 10 minutes on day 6 or 7 of NK3Ra administration or on the equivalent day of the control cycle. Reproductive hormones
and ultrasound scan findings were compared with those of the control cycle, the order of which was randomized. BD, twice daily; LMP, last
menstrual period; NMP, next menstrual period; TV USS, transvaginal ultrasonography.
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progesterone levels and cycle length were compared by
Student t test. Characteristics of LH pulsatile secretion were
compared by paired Student t test.
Data are presented as mean 6 standard error of the mean.
Data not normally distributed were log-transformed before
statistical analysis. Differences were regarded as significant at a
two-sided P, 0.05. The statistical software package GraphPad
Prism 7 (GraphPad Software, San Diego, CA) was used.
Ethical approval
The study protocol was approved by South East Scotland
Research Ethics Committee (Reference 09/S1101/67). This
study was formally assessed as not being a clinical trial of an
investigational medicinal product and, therefore, was not linked
to trials databases.
Results
Baseline characteristics
Eachwoman took part in control and treatment cycles,
which were comparable by cycle day on which the study
had started; baseline serum LH, FSH and estradiol
concentrations; the size of the largest ovarian follicle
present at that time; and the cycle day for assessment of
LH pulsatility (Table 1).
Basal and pulsatile gonadotropin secretion
NK3R antagonism had no effect on LH secretion by
single timepoint analysis throughout 7 days of admin-
istration (Fig. 2A) or by hourly analysis during 8 hours
of frequent LH sampling after dosing on day 6 or 7
of NK3Ra treatment and on the equivalent day of the
control cycle (Fig. 2B). However, deconvolutional anal-
ysis of pulsatile LH secretion, performed in eight of the
13 women on day 6 or 7 of NK3Ra treatment (cycle day
10.96 0.2) and on the equivalent day of the control cycle
(cycle day 11.16 0.5), showed differences in pulsatile LH
secretion between treatment and control cycles. An ex-
ample of an LHpulse frequency profile is shown in Fig. 3A
and the pulse profile for each participant is summarized in
Supplemental Table 1. LH pulse frequency did not change
with NK3Ra treatment [0.696 0.1 pulses/h vs 0.666 0.1
pulses/h in control cycles; nonsignificant (ns)], but basal
(i.e., nonpulsatile) LH secretion was reduced (P , 0.05;
Fig. 3B and 3C).NK3Ra had no effect on secretorymass of
LH per pulse (Fig. 3D) and total amount of LH secreted
in a pulsatile manner (Fig. 3E). A slight increase in the
orderliness (i.e., decrease in the approximate entropy) of
LH secretory pattern with the NK3Ra approached sta-
tistical significance (P = 0.054; Fig. 3F).
After discontinuation of MLE4901 treatment, an LH
surge was detected on cycle day 22 6 1 vs 15 6 1 in
control cycles (P = 0.0006; Fig. 2A and Fig. 4A). There
was no effect on the magnitude of the peak of midcycle
LH secretion (23.4 6 4.8 IU/L vs 19.7 6 3.2 IU/L in
control cycles; ns).
FSH secretion was unchanged with the NK3Ra by
single-day sampling (Fig. 2C). To detect subtle changes
in hormone secretion over time potentially overlooked
by performing single-time spot blood sampling, a more
detailed analysis of FSH secretion every hour for 8 hours
after NK3Ra dosing showed higher FSH concentrations
throughout the 8-hours during NK3Ra administration
comparedwith control cycles (ANOVAP, 0.03 andP,
0.05 for NK3Ra cycle vs control cycles at every hour;
Fig. 2D).
Follicular phase estradiol and inhibin B secretion
Serum concentrations of estradiol were affected by
NK3Ra administration (Fig. 2E). Estradiol concen-
trations were significantly lower at each time point
throughout treatment (P, 0.05 vs control cycles) and, at
the end of NK3Ra administration, estradiol concentra-
tions were markedly lower than in control cycles (166 6
29 pmol/L vs 446 6 86 pmol/L, respectively, on day 12;
P , 0.0001), remaining comparable to baseline levels
on cycle day 5 (166 6 29 pmol/L at end of treatment
vs 122 6 14 pmol/L on day 5; ns). Over the days after
discontinuation of NK3Ra treatment, estradiol concentra-
tions rose, reaching preovulatory levels comparable those
in control cycles (690 6 68 pmol/L vs 699 6 62 pmol/L,
respectively; ns) but 7 days later (cycle day 216 1vs 146 1,
respectively; P = 0.002; Fig. 4B). Inhibin B concentrations
were slightly reduced during NK3Ra administration, but
this did not reach statistical significance (Fig. 2F).
Follicle growth, the timing of ovulation, and
endometrial development
Follicle growth was suppressed in NK3Ra treatment
cycles, matching the effects on estradiol secretion. Figure 5A
shows follicle growth until ovulation for eachwoman in the
Table 1. Baseline Characteristics of Study
Participants (n = 13)
Characteristic
Control
Cyclea
NK3Ra
Cyclea P Value
Cycle day study
commenced
5.6 6 0.2 5.0 6 0.2 0.06
LH, IU 4.9 6 0.5 4.8 6 0.4 0.98
FSH, IU 5.1 6 0.8 5.3 6 0.9 0.82
Estradiol, pmol/L 160 6 19 126 6 13 0.07
Follicle diameter, mm 8.4 6 0.4 8.1 6 0.3 0.54
Cycle-day pulsatility
study
11.1 6 0.5 10.9 6 0.2 0.75
LH pulses/h at baseline 0.69 6 0.1 N/A N/A
Data given as mean 6 SEM.
Abbreviation: N/A, not applicable.
aControl and NK3Ra-treated cycles were comparable by starting cycle
day, reproductive hormone levels, and the size of the largest ovarian
follicle.
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control and NK3Ra-treated cycles; the mean data are
shown in Fig. 5B. Although there was a progressive rise in
diameter of the leading follicle in control cycles, this did not
occur during the 7 days of NK3Ra treatment (P = 0.0003).
The diameter of the leading follicle was significantly smaller
than in control cycles at each time point throughout the
7 days of treatment (P , 0.05 vs pretreatment) and at the
end of treatment with the NK3Ra [i.e., on cycle day 12
(9.3 6 0.4 mm vs 15.1 6 0.9 mm; P , 0.0001; Fig. 5B)].
After treatment, normal follicle growth resumed, reaching
the same preovulatory follicle size as in control cycles
(16.1 6 0.7 mm with NK3Ra vs 17.260.7 mm in control
Figure 2. Reproductive hormone response in premenopausal women in the control and NK3Ra-treated cycles (n = 13). Mean serum (A) LH level
during single timepoint sampling and (B) during 8 hours of frequent sampling every 10 minutes on day 6 to 7 of NK3Ra administration. (C) FSH
level during single timepoint sampling and (D) during 8 hours of frequent sampling every hour on day 6 to 7 of NK3Ra administration. (E) Estradiol,
(F) inhibin B secretion, and (G) urinary progesterone/creatinine ratio in premenopausal women (n = 11) adjusted to LH surge onset day
0 with and without NK3Ra was compared in premenopausal women by repeated measure two-way ANOVA at time points when paired data
were available, followed by Bonferroni multiple comparisons post hoc analysis. Data are given as mean 6 SEM. *P , 0.05; **P , 0.01;
***P , 0.001; ****P , 0.0001.
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cycles; ns) but later (cycle day 21 6 1 vs 15 6 1; P =
0.002; Fig. 4C). Consistent with the delay in the timing
of the LH surge, NK3Ra treatment delayed the ultrasound-
determined day of ovulation in 11 of 13 subjects (Fig. 5C).
Endometrial development was also affected by NK3Ra
treatment (P , 0.0001); the endometrium was signifi-
cantly thinner than in control cycles at the end of
treatment (4.6 6 0.4 mm vs 7.7 6 0.5 mm, respectively,
on day 12; P, 0.0001; Fig. 5D). Thereafter, endometrial
thickness increased, reaching a similar thickness to that in
control cycles at the time of ovulation (8.9 6 0.6 mm vs
9.5 6 1.0 mm, respectively; ns).
Luteal progesterone secretion and cycle length
Consistentwith the demonstration of delayedovulation,
NK3Ra treatment delayed the cycle day of peak midluteal
progesterone (cycle day 30 6 2 vs 22 6 1; P = 0.002; Fig.
4D). However, when standardized against the day of the
LH surge, luteal function was not affected by the NK3Ra
(urinary progesterone level, 58610 pmol/mol vs 4867
pmol/mol creatinine on LH surge day +7; ns; Fig. 2G).
Menstrual cycle length was prolonged, on average, by
6 days in the NK3Ra treatment cycle (356 1 days vs 296
1 days; P = 0.0003; Fig. 4E).
Tolerability and safety
MLE4901 was well tolerated with no treatment dis-
continuations. Hematology and biochemistry (including
liver function) safety parameters remained stable in all
participants throughout the study (Supplemental Ta-
ble 2). No participants had elevated liver function pa-
rameters related to drug administration. One woman’s
bilirubin level was 1.4-fold higher than the upper range of
laboratory reference pretreatment (within the limits of
protocol allowance) with no change during treatment or
thereafter. All participants returned to their usual men-
strual cycle length after NK3Ra treatment.
Discussion
This study investigated the role of the NKB pathway in
regulating physiological follicle development and its
hypothalamic regulation through the modulation of
pulsatile GnRH and LH secretion in healthy women. This
period of the cycle includes emergence of the dominant
follicle and its growth toward ovulation, and thus is
critical for female cyclicity and fertility. NK3R antago-
nism for 7 days in the early follicular phase in healthy
women suppressed follicle growth and estradiol secre-
tion, and delayed ovulation by the duration of treatment.
NK3Ra suppressed basal LH secretion without a change
in pulse frequency, detected by frequent blood sampling
following drug administration, but LH concentration by
once-daily sampling 12 hours after the previous NK3Ra
dose was unchanged. The half-life of MLE4901 is ap-
proximately 8.5 hours (26). FSH secretion was increased
Figure 3. Pulsatile LH secretion in premenopausal women in the control and NK3Ra-treated cycles (n = 8). (A) Illustrative LH pulse profile from
one participant who underwent blood sampling every 10 minutes for LH for 8 hours with no NK3Ra (closed circles) and on day 7 of NK3Ra
treatment (open squares). Mean (B) LH pulse frequency, (C) basal (nonpulsatile) LH secretion, (D) mass of LH per pulse, (E) pulsatile LH secretion,
and (F) relative orderliness or regularity of LH secretory pattern were compared between the control and NK3Ra-treated cycles. Data are given as
mean 6 SEM. *P , 0.05. ApEn, approximate entropy.
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during treatment, likely reflecting the reduced estradiol
concentrations. FSH secretion is also promoted (relative
to LH) by basal rather than pulsatile GnRH secretion
(27), thus two mechanisms may contribute to the raised
FSH concentrations observed with the NK3Ra. These
findings demonstrate that selective blockade of NK3R
regulates ovarian function by reducing basal GnRH and
LH secretion in the midfollicular phase, and this effect
persisted for the duration of treatment. This confirms an
important role of NKB in human reproduction and,
furthermore, provides evidence forNKB-NK3R signaling
in the physiological regulation of normal follicle devel-
opment in women.
A striking finding was that the effects of the NK3Ra
were reversible after discontinuation of treatment, with
normal follicular estradiol production and growth re-
suming, resulting in a normal LH surge and midluteal
progesterone rise, all of which were delayed by the du-
ration of treatment. Thus, although basal LH secretion
was reduced during treatment, there remained sufficient
gonadotropin support to the emerging dominant follicle
to prevent atresia, although whether oocyte quality might
have been compromised is unclear.
The decreased estradiol secretion for the duration
of the 7 days of treatment was biologically relevant,
as shown by lack of endometrial development during
NK3Ra treatment, with subsequent growth to normal
preovulatory thickness as follicle estradiol production
increased after drug discontinuation. A different NK3Ra
(ESN364) administered to healthy women for 21 days
throughout the follicular phase did not result in any
significant suppression in follicle growth, despite other
findings being consistent with our data, particularly a
delayed LH surge in some women and prolongation of
menstrual cycle length (22). It is likely that the more
variable effect in that study between different women
precluded clear demonstration of an effect on folliculo-
genesis. Although these data show that dominant follicle
development was delayed by treatment with the NK3Ra,
there was no clear evidence of an effect on the growth of
Figure 4. Summary of the delay in timing of key events in female reproduction with the NK3Ra compared with no-treatment control cycles in
premenopausal women. Individual response of the participants (n = 13) to NK3Ra showing the day of the menstrual cycle for (A) LH surge, (B)
peak estradiol, (C) appearance of the largest diameter of the preovulatory follicle, (D) midluteal urinary progesterone (day of LH surge +7; n = 11),
and (E) the length of menstrual cycle. **P , 0.01; ***P , 0.001.
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smaller follicles, as indicated by nonsignificant changes in
inhibin B levels.
The recovery of LH and FSH concentrations 12 hours
after dosing may indicate that the dose and regimen used
in this study are at the bottom of the dose-response curve.
Similarly, ovulation was delayed in 11 of the 13 women,
and two women were nonresponders. It is possible that
with higher doses of NK3Ra and longer duration of
exposure, a more marked inhibitory action on LH se-
cretion would be observed, potentially leading to follicle
atresia and a decline in estradiol concentrations. Con-
versely, although follicle growth was arrested during
7 days of NK3Ra treatment, it remains unclear if such
effect would persist with longer use. Nevertheless, con-
sistent with suppressive effects on basal LH secretion
during frequent blood sampling, antagonism of NK3R
resulted in marked ovarian effects: Follicle maturation
and ovarian hormone secretionwere delayed, postponing
the LH surge and subsequent luteal progesterone rise. The
lower serum estradiol levels observed with the NK3Ra
treatment suggests that LH dependent secretion of thecal
androgens was suppressed. Granulosa cell proliferation
(and, thus, follicle growth) is predominantly driven
by FSH, which was not suppressed but rather increased
by the NK3Ra. It may be that the NK3Ra, therefore,
impaired follicle function through direct intrafollicular
mechanisms, because NK3R has been localized to human
granulosa cells (28–30). The results of this study, how-
ever, are in contrast to the suppressive effects of GnRH
antagonists, and of the kisspeptin analog TAK448 (31),
which, like GnRH agonists, resulted in an initial stimu-
lation of LH secretion followed by suppression. Estradiol
levels remained.100 pmol/L in this study. This alleviates
concerns of unwanted menopausal-like adverse effects,
which are associated with the use of GnRH analogs (32).
Selective blockage of NKB signaling, therefore, might
have therapeutic potential in the management of sex-
steroid dependent disorders, such as endometriosis, fi-
broids, and heavy menstrual bleeding, and potentially
as a nonsteroidal contraceptive.
This study investigated in detail a hypothalamic mode
of action of NKB during the follicular phase of the
menstrual cycle in healthy women, showing that, in the
follicular phase, NK3Ra reduced basal LH levels (i.e.,
the amount of LH secreted between the pulses) and, by
inference, GnRH secretion, with no effect on pulse fre-
quency. This indicates that basal rather than pulsatile LH
secretion may be more important in supporting mid-
follicular phase follicle growth, with pulsatile secretion
Figure 5. Follicle and endometrial development in 13 premenopausal
women in the control and NK3Ra-treated cycles until ovulation. (A)
Follicle growth in each of the 13 premenopausal women showed
delayed development with the NK3Ra treatment (open squares)
compared with the control cycle (closed circles). (B) Mean follicle
diameter in the control and NK3Ra-treated cycle. Data include all
cycles in which the leading follicle remained (i.e., data only include
women who had not yet ovulated at the later time points). (C)
Table showing the time point in the control and NK3Ra cycle at
which the leading follicle was no longer identified at transvaginal
Figure 5. (Continued). ultrasonography. (D) Endometrial development
in premenopausal women in control and NK3Ra-treated cycles.
Data are given as mean 6 SEM. *P , 0.05; ****P , 0.0001.
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and frequency becomingmore important in the lead up to
ovulation, as occurs physiologically (33). We have re-
cently demonstrated that the dose of MLE4901 used in
this study reduced LH pulse frequency and abolished the
correlation between estradiol and LH response to kiss-
peptin in a model of estrogen-induced LH secretion (20),
which is in contrast to the absence of effect on LH pulse
frequency observed in the current study in women with
lower estradiol during early follicular phase. This sug-
gests that estrogen feedback may have a role in modu-
lating NKB effects on GnRH and LH secretion. The
absence of effect on LH pulse frequency shown in the
current study may reflect lower estradiol feedback (25),
but may also reflect differences in the settings of the
pathways driving GnRH pulse frequency in the early
follicular phase. Reduction in the frequency of LH and
GnRH pulses by the NK3Ra has been demonstrated
previously in states of high LH output, in women with
PCOS (21) and in gonadectomized ewes and male
monkeys (16, 19). Patients with inactivating mutations in
the NKB pathway had diminished LH pulse frequency
(34); therefore, it remains possible that with larger doses
of the NK3Ra, such an effect would be observed in
healthy women in the follicular phase of the menstrual
cycle. This study may also be underpowered to detect
changes in LH pulse frequency.
In summary, NK3R antagonism in healthy pre-
menopausal women in the early and midfollicular phase
of the menstrual cycle resulted in reduced LH secretion,
prevented follicle growth and rising estradiol secretion,
and delayed ovulation by the duration of treatment.
Those effects were reversible after cessation of drug ad-
ministration, with evidence of normal ovulation and
luteal function. These data confirm the involvement of
NKB in the physiological neuroendocrine control of fe-
male reproduction, with potential therapeutic application
in the management of sex steroid–dependent disorders.
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